Policy

Ian Neeland, MD, of University Hospitals and Case Western Reserve University, recommended a team-based, comprehensive approach to managing diabetes and its related complications.

According to some reports, the draft rule imposes strict limitations on telehealth prescriptions even as advocates push for extension of current flexibilities.

The authors assessed what attributes make provider networks adequate in the eyes of consumers, including travel times, inclusive care, and language access.

The obesity epidemic is a global crisis, with experts from around the world emphasizing the importance of short-term strategies, long-term solutions, and multidisciplinary collaboration as they advocate for the heart health of their patients.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

Providing health care for Olympic athletes can put a heavy burden on both the competitors and their doctors to deliver that care and to pay for such care in the long term.

The closures highlight financial challenges that rural hospitals face amid workforce shortages, rising costs, and leveling reimbursement.

Thyme Care welcomes its new senior vice president to lead initiatives in value-based oncology care.

This second installment on the threat of forever chemicals examines the impactful policies brought about during the Biden-Harris administration that are set to play a role in the future manufacturing, use, and monitoring of these harmful substances.

Aetna has become the first major US insurer to expand access to fertility services by covering intrauterine insemination as a medical benefit for all eligible plans, marking a significant move toward greater equity in family-building options for people of all backgrounds.

Medicare has not clearly defined what constitutes "established cardiovascular disease," leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.

New research reveals the first documentation of a significant rise in heat-related mortality rates in the US through 2023, contrasting with earlier studies that indicated a declining trend.

Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.

Disparities in hypertension brought on by neighborhood deprivation were most prominently found in Black patients.

The researchers found inferior outcomes and higher accrued costs associated with alloimmunization in patients with myelodysplastic syndromes (MDS), a disease that relies on transfusion of red blood cells.

Spotty vaccine supplies have consumers searching for protection as the FDA prepares to approve updated COVID-19 shots.

The birth rate in the US continues its 17-year decline, with fertility levels now at their lowest in decades, according to CDC data.

The majority of federal savings indicated by the Inflation Reduction Act's Drug Price Negotiation Program can be attributed to 3 drugs.

Changes in formulary coverage for 2024 are impacting Medicare patients' access to and ability to afford various prescription medications.

Adverse outcomes in the aftermath of the COVID-19 pandemic continue to be evaluated as they pertain to social determinants of health, with these authors investigating improvements in food hardship among families participating in the Supplemental Nutrition Assistance Program (SNAP).

Some groups praised CMS after it announced the 10 negotiated Medicare drug prices while others criticized its potential impacts on drug competition and development.

Health plans can improve their Medicare Advantage Star Ratings by focusing on member relationships, ensuring proper documentation, grouping measures, staying updated with regulatory changes, and optimizing their strategy based on numerical targets.

This article first appeared on The Center for Biosimilars®.